Stock Analysis, Dividends, Split History

PAHC / Phibro Animal Health Corporation financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price43.35
Volume198,700.00
Market Cap ($M)885.76
Enterprise Value ($M)1,086.40
Book Value ($M)184.95
Book Value / Share9.14
Price / Book4.79
NCAV ($M)-71.26
NCAV / Share-3.52
Price / NCAV-12.43
Share Statistics
Common Shares Outstanding2 20,246,034
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 20,121,674
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.16
Return on Assets (ROA)0.10
Return on Equity (ROE)0.43
Balance Sheet (mrq) ($M)
Assets671.68
Liabilities486.73
Quick Ratio1.66
Current Ratio2.90
Income Statement (mra) ($M)
Revenues819,982,000.00
Operating Income98.93
Net Income64.88
Earnings Per Share Diluted1.61
Earnings Per Share Basic1.61
Cash Flow Statement (mra) ($M)
Cash From Operations70.01
Cash from Investing-84.61
Cash from Financing-84.61
Identifiers and Descriptors
CUSIP71742Q106
Central Index Key (CIK)1069899
Related CUSIPS
71742Q956

Split History

Stock splits are used by Phibro Animal Health Corporation to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

16h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

18h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Here's Why You Should Invest in Phibro (PAHC) Right Now

2018-08-30 zacks
Phibro Animal Health Corporation (PAHC - Free Report) has been gaining investor confidence on stellar results over an extended period. Over the past year, the company’s stock has outperformed its industry. The stock has gained 32.4% compared with the industry’s 21.5% gain.

Phibro Animal Health Corporation 2018 Q4 - Results - Earnings Call Slides

2018-08-29 seekingalpha
The following slide deck was published by Phibro Animal Health Corporation in conjunction with their 2018 Q4 earnings call.

Phibro Animal Health Corporation (PAHC) CEO Jack Bendheim on Q4 2018 Results - Earnings Call Transcript

2018-08-28 seekingalpha
Phibro Animal Health Corporation (NASDAQ:PAHC) Q4 2018 Earnings Conference Call August 28, 2018 9:00 AM ET

Phibro Animal (PAHC) Q4 Earnings Beat, Sales Improve Y/Y

2018-08-28 zacks
Phibro Animal Health Corporation (PAHC - Free Report) reported adjusted earnings per share (EPS) of 46 cents in the fourth quarter of fiscal 2018, up 17.9% year over year. Adjusted EPS surpassed the Zacks Consensus Estimate of 44 cents.

PetMed Express: Buy The Dip

2018-07-30 seekingalpha
There's a decent bear case for PETS, given rising competition, its "gray market" business model, and what looks like margin pressure ahead.

CUSIP: 71742Q106